-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Talk 3 Bispecific, Trispecific, and Other Novel Immune Treatments in Myeloma

Program: Education Program
Session: Immunotherapy in Multiple Myeloma
Sunday, December 6, 2020, 9:25 AM-9:30 AM

Ajai Chari, MD

Mt. Sinai School of Medicine, New York, NY

Disclosures: Chari: Novartis: Honoraria; Secura Bio: Consultancy; Celgene: Consultancy, Research Funding; Glaxo Smith Kline: Consultancy; Amgen: Consultancy, Research Funding; Bristol Myers Squibb: Consultancy; Pharmacyclics: Research Funding; Karyopharm: Consultancy; Sanofi Genzyme: Consultancy; Seattle Genetics: Consultancy, Research Funding; Oncopeptides: Consultancy; Takeda: Consultancy, Research Funding; Antengene: Consultancy; Janssen: Consultancy, Research Funding; Adaptive Biotechnology: Honoraria; The Binding Site: Honoraria; Array BioPharma: Honoraria.

See more of: Immunotherapy in Multiple Myeloma
See more of: Education Program
<< Previous Presentation | Next Presentation